Format

Send to

Choose Destination
J Am Acad Dermatol. 2020 Jan 10. pii: S0190-9622(20)30048-7. doi: 10.1016/j.jaad.2019.12.068. [Epub ahead of print]

Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes.

Author information

1
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
2
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
3
Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
4
Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
5
Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
6
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: nleboeuf@bwh.harvard.edu.

KEYWORDS:

Autoimmune; BP; ICI; PD-1; PD-L1; blistering; bullous pemphigoid; cancer; dAE; dermatologic adverse event; immune checkpoint inhibitor; immunotherapy; nivolumab; oncodermatology; oncology; pembrolizumab; programmed death ligand-1; programmed death-1

PMID:
31931083
DOI:
10.1016/j.jaad.2019.12.068

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center